Placebo-Controlled Trials of Blood Pressure-Lowering Therapies for Primary Prevention of Dementia
To the Editor: Hypertension at middle age is a risk factor for vascular and neurodegenerative dementia later in life. 1 Because populations are aging, the number of demented patients will grow 2-fold every 20 years, from 24.3 million people in 2000 to 81.1 million by 2040, with Ͼ60% living in developing countries. 2 The question of whether hypertension is a modifiable risk factor for dementia is therefore of great clinical importance. Our 2007 meta-analysis 1 included 4 placebo-controlled trials of blood pressure-lowering therapies for prevention of dementia (18 196 patients and 642 dementia cases). [3] [4] [5] [6] The common odds ratio was 0.89 (CI, 0.75 to 1.04) and did not reach statistical significance (Pϭ0.15). However, sensitivity analyses revealed a difference (Pϭ0.04) that depended on whether active treatment started with or included a diuretic or dihydropyridine calcium channel blocker compared with an inhibitor of the renin system. The pooled odds ratios were 0.75 (CI, 0.60 to 0.94; Pϭ0.01) for Systolic Hypertension in the Elderly Program (SHEP), 3 SystEur, 5 and the combination therapy arm of PROGRESS, 4 and 1.08 (CI, 0.84 to 1.38; Pϭ0.54) for SCOPE 6 and the perindopril-only subgroup of the PROGRESS trial. 4 Since our 2007 review, 1 4 additional placebo-controlled trials reported on the prevention of dementia by blood pressurelowering therapies, including ADVANCE, 7 HYVET-COG, 8 PRoFESS, 9 and, most recently, TRANSCEND. 10 We therefore updated our meta-analysis ( Figure) . In all trials combined, blood pressure lowering did not reduce the risk (Ϫ5%). For trials involving a diuretic or dihydropyridine calcium channel blocker as part of active treatment, the reduction was significant (Ϫ18%), whereas this was not the case in trials of renin system inhibitors (ϩ1). This difference between drug classes might be explained by the amount of blood pressure reduction because in weighted metaregression analysis, lowering of systolic pressure explained 41% (Pϭ0.08) of the risk reduction. However, several quantitative overviews [11] [12] [13] support the idea that diuretics and dihydropyridine calcium channel blockers have a small (5% to 10%) benefit beyond blood pressure lowering in the prevention of stroke. Moreover, 2 trials, respectively on prevention 5 10 Pooled estimates of the between-group differences in systolic blood pressure (⌬SBP) and median or average follow-up (FU) were weighted for the number of patients. DIU indicates diuretic; CCB, calcium channel blocker; ACEI, angiotensinconverting enzyme inhibitor; ARB, angiotensin receptor blocker. progression 14 of dementia, showed positive effects of dihydropyridine calcium channel blockers. Experimental studies, reviewed in this journal, 1 also support the hypothesis that inhibiting the inward current of calcium ions in neuronal cells protects against necrosis and apoptosis. In conclusion, the issue of whether blood pressure lowering reverses the risk of Alzheimer's disease remains unsettled. A sufficiently powered trial comparing a diuretic or long-acting dihydropyridine calcium channel blocker with a renin system inhibitor in the primary prevention of dementia is needed, but such an orphan trial will not easily find a sponsor unless public agencies take up the challenge. 
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